Literature DB >> 17714706

Cortical cholinergic deficiency enhances amphetamine-induced dopamine release in the accumbens but not striatum.

Anna Mattsson1, Lars Olson, Torgny H Svensson, Björn Schilström.   

Abstract

Cholinergic dysfunction has been implicated as a putative contributing factor in the pathogenesis of schizophrenia. Recently, we showed that cholinergic denervation of the neocortex in adult rats leads to a marked increase in the behavioral response to amphetamine. The main objective of this study was to investigate if the enhanced locomotor response to amphetamine seen after cortical cholinergic denervation was paralleled by an increased amphetamine-induced release of dopamine in the nucleus accumbens and/or striatum. The corticopetal cholinergic projections were lesioned by intraparenchymal infusion of 192 IgG-saporin into the nucleus basalis magnocellularis of adult rats. Amphetamine-induced dopamine release in the nucleus accumbens or striatum was monitored by in vivo microdialysis 2 to 3 weeks after lesioning. We found that cholinergic denervation of the rat neocortex leads to a significantly increased amphetamine-induced dopamine release in the nucleus accumbens. Interestingly, the cholinergic lesion did not affect amphetamine-induced release of dopamine in the striatum. The enhanced amphetamine-induced dopamine release in the nucleus accumbens in the cholinergically denervated rats could be reversed by administration of the muscarinic agonist oxotremorine, but not nicotine, prior to the amphetamine challenge, suggesting that loss of muscarinic receptor stimulation is likely to have caused the observed effect. The results suggest that abnormal responsiveness of dopamine neurons can be secondary to cortical cholinergic deficiency. This, in turn, might be of relevance for the pathophysiology of schizophrenia and provides a possible link between cholinergic disturbances and alteration of dopamine transmission.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17714706     DOI: 10.1016/j.expneurol.2007.07.012

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  5 in total

1.  Effects of nucleus accumbens amphetamine administration on performance in a delay discounting task.

Authors:  Caitlin A Orsini; Marci R Mitchell; Sara C Heshmati; Kristy G Shimp; Megan S Spurrell; Jennifer L Bizon; Barry Setlow
Journal:  Behav Brain Res       Date:  2017-01-03       Impact factor: 3.332

2.  Ventral and dorsal striatal dopamine efflux and behavior in rats with simple vs. co-morbid histories of cocaine sensitization and neonatal ventral hippocampal lesions.

Authors:  Robert Andrew Chambers; Alena M Sentir; Eric A Engleman
Journal:  Psychopharmacology (Berl)       Date:  2010-07-15       Impact factor: 4.530

3.  Neuropathological changes in the nucleus basalis in schizophrenia.

Authors:  M R Williams; R Marsh; C D Macdonald; J Jain; R K B Pearce; S R Hirsch; O Ansorge; S M Gentleman; M Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-12-11       Impact factor: 5.270

4.  Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease.

Authors:  Suzanne Reeves; Richard Brown; Robert Howard; Paul Grasby
Journal:  Neurology       Date:  2009-02-10       Impact factor: 9.910

5.  Neuroprotective effects of donepezil against cholinergic depletion.

Authors:  Debora Cutuli; Paola De Bartolo; Paola Caporali; Anna Maria Tartaglione; Diego Oddi; Francesca Romana D'Amato; Annalisa Nobili; Marcello D'Amelio; Laura Petrosini
Journal:  Alzheimers Res Ther       Date:  2013-10-24       Impact factor: 6.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.